Ascletis PharmaASCLF -4.00%38 Quick Ratio is 15.04 as of Dec. 2025, which is 25% below its 10-year median of 19.94. GuruFocus rates ASCLF with a GF Score™ of 38/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,411 Biotechnology companies, Ascletis Pharma ranks better than 87.17% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Ascletis Pharma's quick ratio for the quarter that ended in Dec. 2025 was 15.04.
Ascletis Pharma has a quick ratio of 15.04. It generally indicates good short-term financial strength.
The historical rank and industry rank for Ascletis Pharma's Quick Ratio or its related term are showing as below:
ASCLF'
s Quick Ratio Range Over the Past 10 Years
Min: 6.09 Med: 19.94 Max: 37.56
Current: 15.04
During the past 10 years, Ascletis Pharma's highest Quick Ratio was 37.56. The lowest was 6.09. And the median was 19.94.
ASCLF's Quick Ratio is ranked better than 87.17% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs ASCLF: 15.04
Ascletis Pharma (OTCPK:ASCLF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Ascletis Pharma Quick Ratio Related Terms
Ascletis Pharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for Ascletis Pharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ascletis Pharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Ascletis Pharma's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascletis Pharma (ASCLF) has a Quick Ratio of 15.04 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Ascletis Pharma and its competitors. This is 25% below median its historical median of 19.94. Over the past decade, Ascletis Pharma's Quick Ratio has ranged from 6.09 to 37.56. According to the industry distribution chart, Ascletis Pharma ranks #181 out of 1411 companies in the Biotechnology industry, placing it in the top 12.8%.
Is Ascletis Pharma's Quick Ratio too high?
Ascletis Pharma's current Quick Ratio of 15.04 is 25% below median its 10-year median of 19.94. Over the past 10 years, this metric has ranged from a low of 6.09 to a high of 37.56. The Biotechnology industry median Quick Ratio is 3.59. Ascletis Pharma's value of 15.04 is 318.9% above this industry median. Based on the distribution chart, Ascletis Pharma ranks #181 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #181 out of 1411 companies for Quick Ratio. This places Ascletis Pharma in the top 13% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.59. Ascletis Pharma's value of 15.04 is 318.9% above this benchmark. Historically, Ascletis Pharma's own Quick Ratio has ranged from 6.09 to 37.56 over the past decade. While the company's 10-year median is 19.94 vs. the industry median of 3.59, Ascletis Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascletis Pharma's current Quick Ratio of 15.04 is 318.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Ascletis Pharma and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascletis Pharma's current Quick Ratio is 15.04, which is 25% below median its own 10-year median of 19.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.44 — trading 7100% above its estimated fair value. The current Quick Ratio is 15.04, which is 25% below median its 10-year median of 19.94 and 318.9% above the Biotechnology industry median of 3.59. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current Quick Ratio is 15.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (ASCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for ASCLF:
Quick Ratio: 15.04 (25% below median its 10-year median of 19.94)
GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
Industry Position: 318.9% above the Biotechnology median (#181 of 1411)
No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score
Get the complete analysis for ASCLF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASCLF has been successfully added to your 
